BCLI · XBRL financial data
Brainstorm Cell Therapeutics financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (BCLI's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | †Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 3 | 2* | 1 | 1 | 1 | 2* | 1 | 1 | 1 | 1* | 1 | 1 |
| General and administrative | 3 | 3* | 2 | 2 | 2 | 1* | 2 | 1 | 1 | 1* | 1 | 3 |
| Operating income (loss) | (6) | (5)* | (2) | (3) | (3) | (3)* | (3) | (3) | (2) | (2)* | (2) | (4) |
| Net income (loss) | (1) | (6)* | (3) | (3) | (3) | (3)* | (3) | (3) | (2) | (2)* | (2) | (4) |
| Earnings per share, basic‡ USD per share | (6.68) | (24.50)* | (11.14) | (8.91) | (7.61) | (7.91)* | (0.45) | (0.34) | (0.19) | — | (0.19) | (0.35) |
| Earnings per share, diluted‡ USD per share | (6.68) | (24.50)* | (11.14) | (8.91) | (7.61) | (7.91)* | (0.45) | (0.34) | (0.19) | — | (0.19) | (0.35) |
| Weighted average shares, basic‡ millions of shares | 0 | 0* | 0 | 0 | 0 | 0* | 6 | 9 | 11 | 11* | 11 | 11 |
| Weighted average shares, diluted‡ millions of shares | 0 | 0* | 0 | 0 | 0 | 0* | 6 | 9 | 11 | 11* | 11 | 11 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2025); filings made before it reported them unadjusted.
- † Share count changed about 18x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal quarters (BCLI's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | †Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 1 | 1 | 1 | 3 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Short-term investments | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Prepaid and other current assets | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Total current assets | 2 | 2 | 1 | 4 | 0 | 0 | 2 | 2 | 1 | 0 | 0 | 0 |
| Property and equipment, net | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Right-of-use asset | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 6 | 4 | 3 | 6 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 |
| Accounts payable | 4 | 5 | 5 | 5 | 5 | 6 | 7 | 6 | 6 | 7 | 7 | 7 |
| Accrued liabilities | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Total current liabilities | 6 | 8 | 7 | 8 | 7 | 9 | 11 | 9 | 9 | 11 | 12 | 12 |
| Lease liability, non-current | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — |
| Total liabilities | 8 | 9 | 9 | 9 | 8 | 10 | 11 | 9 | 9 | 11 | 12 | 12 |
| Accumulated deficit | (209) | (215) | (218) | (221) | (224) | (227) | (230) | — | (235) | (237) | (239) | (243) |
| Total stockholders' equity | (3) | (5) | (6) | (4) | (6) | (8) | (7) | (6) | (8) | (10) | (11) | (12) |
| Total liabilities and equity | 6 | 4 | 3 | 6 | 2 | 2 | 4 | 3 | 1 | 1 | 1 | 1 |
| Common shares outstanding (cover page)‡ millions of shares | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 10 | 11 | 11 | 11 | 11 |
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2024); filings made before it reported them unadjusted.
- ‡ Per-share figures and share counts are adjusted for the 1-for-14.925373134328357 stock split (September 2025); filings made before it reported them unadjusted.
- † Share count changed about 18x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal quarters (BCLI's year ends in late December)
| In millions of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | †Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (1) | (6)* | (3) | (3) | (3) | (3)* | (3) | (3) | (2) | (2)* | (2) | (4) |
| Stock-based compensation | 1* | (0)* | 0 | 0* | 0* | 0* | 1 | 1* | 0* | 0* | — | — |
| Net cash from operating activities | (6) | (3)* | (3) | (2) | (3) | (1)* | (2) | (4) | (1) | (1)* | (1) | (1) |
| Purchases of property and equipment | 0 | 0* | — | — | — | — | — | — | — | — | — | — |
| Net cash from investing activities | (0) | 0* | — | — | — | year only | — | — | — | — | — | — |
| Proceeds from issuing common stock | 2* | (161)* | 174 | 4* | 0* | 2* | 182,000 | (181,815)* | — | year only | 0 | 0* |
| Net cash from financing activities | 7 | 3* | 3 | 4 | 0* | 1* | 3 | 3 | 0 | 1* | 1 | 1 |
| Net change in cash | 1 | 0* | (1) | 3 | (3) | 0* | 1 | (1) | (1) | 0* | (0) | 0 |
- † Share count changed about 18x in the period ending 2025-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics | 0 | not reported | (0.9) | 11.0M | 0.0 quarters | 10-QJun 30, 2026 |
| Kiora Pharmaceuticals | 7.1 | not reported | (1.9)* | 4.4M | 8.9 quarters | 10-QJun 30, 2026 |
| Scienture Holdings | 8.2 | 0.3 | (3.1)* | 41.1M | 2.6 quarters | 10-QJun 30, 2026 |
| LeonaBio | 32 | not reported | (17)* | 9.4M | 3.0 quarters | 10-QJun 30, 2026 |
| Mannatech | 6 | 27 | (0.8)* | 1.9M | 7.6 quarters | 10-QJun 30, 2026 |
| Palisade Bio | 125 | 0.5 | (7.6)* | 174.3M | 16.5 quarters | 10-QJun 30, 2026 |
| Phio Pharmaceuticals | 13 | not reported | (4)* | 11.6M | 3.2 quarters | 10-QJun 30, 2026 |
| Traws Pharma | 5 | not reported | (7.5)* | 15.4M | 0.7 quarters | 10-QJun 30, 2026 |
| BioCardia | 4.1 | not reported | (1.7)* | 15.1M | 2.4 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.